Basic Information
RNALocate ID: | RLID:11000851 |
RNA Symbol: | hsa-miR-26a-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-26a |
RNA ID: | miRBase:MIMAT0000082 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 20976003 |
Tissue/Cell Line: | Breast cancer cell line (MCF-7) |
Method: | Microarray |
Description: | Because of the suggested roles of extracellular miRNAs in signaling and diagnosis, we investigated whether the intracellular and extracellular miRNA composition are the same. To answer this question, we performed microRNA microarray analyses of MCF7 cellular (c) and extracellular (x) RNAs (Figure 2A), and found that about 66% of the released miRNAs are at an abundance that closely reflects the cellular miRNA abundance (Figures 2B and 2C). This finding is in agreement with a model wherein most, but not all miRNAs are released passively by mass action. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001347 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001348 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001349 | Cytoplasm | Cell line (HeLa) | 21695135 |
RLID:01001350 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001351 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001352 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001353 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001354 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001355 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001356 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11000849 | Exosome | Human cervical cancer cell line (HeLa) | 25760330 |
RLID:11000850 | Exosome | Glioblastoma cells | 19011622 |
RLID:11000852 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000853 | Exosome | Brain tissue | 23382797 |
RLID:11000854 | Exosome | Plasma | 23663360 |
RLID:11000855 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000856 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
RLID:11000857 | Exosome | Human esophageal cancer cell line (EC9706) | 25184951 |
RLID:11000858 | Microvesicle | Glioblastoma cells | 19011622 |
RLID:11000859 | Microvesicle | Plasma | 23077538 |
RLID:11000860 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000018 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Lymphoma tissue|Mast cells|Seminal fluid|Tongue tissue | |
RLID-D:11000281 | Microvesicle | Blood|Breast cell line|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-26a-5p | Idiopathic pulmonary fibrosis | MNDR-E-MI-33070 |
MNDR | hsa-miR-26a-5p | Diffuse large b cell lymphoma | MNDR-E-MI-33071 |
MNDR | hsa-miR-26a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-33072 |
MNDR | hsa-miR-26a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-33073 |
MNDR | hsa-miR-26a-5p | Oral squamous cell carcinoma | MNDR-E-MI-33074 |
MNDR | hsa-miR-26a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-33075 |
MNDR | hsa-miR-26a-5p | Medulloblastoma | MNDR-E-MI-33076 |
MNDR | hsa-miR-26a-5p | B cell lymphoma of malt type | MNDR-E-MI-33077 |
MNDR | hsa-miR-26a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-33078 |
MNDR | hsa-miR-26a-5p | Lymphoma | MNDR-E-MI-33079 |
MNDR | hsa-miR-26a-5p | Lymphoma non-hodgkin | MNDR-E-MI-33080 |
MNDR | hsa-miR-26a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-33081 |
MNDR | hsa-miR-26a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-33082 |
MNDR | hsa-miR-26a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-33083 |
MNDR | hsa-miR-26a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-33084 |
MNDR | hsa-miR-26a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-33085 |
MNDR | hsa-miR-26a-5p | Niemann-pick disease type c | MNDR-E-MI-33086 |
MNDR | hsa-miR-26a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-33087 |
MNDR | hsa-miR-26a-5p | Anaplastic thyroid cancer | MNDR-E-MI-33088 |
MNDR | hsa-miR-26a-5p | Dermatomyositis | MNDR-E-MI-33089 |
MNDR | hsa-miR-26a-5p | Prostate cancer | MNDR-E-MI-33090 |
MNDR | hsa-miR-26a-5p | Gastric cancer | MNDR-E-MI-33091 |
MNDR | hsa-miR-26a-5p | Gastric lymphoma | MNDR-E-MI-33092 |
MNDR | hsa-miR-26a-5p | Alzheimer disease | MNDR-E-MI-33093 |
MNDR | hsa-miR-26a-5p | Intracranial aneurysm | MNDR-E-MI-33094 |
MNDR | hsa-miR-26a-5p | Bladder cancer | MNDR-E-MI-33095 |
MNDR | hsa-miR-26a-5p | Esophageal carcinoma | MNDR-E-MI-33096 |
MNDR | hsa-miR-26a-5p | Dysautonomia familial | MNDR-E-MI-33097 |
MNDR | hsa-miR-26a-5p | Myotonic dystrophy | MNDR-E-MI-33098 |
MNDR | hsa-miR-26a-5p | Duchenne muscular dystrophy | MNDR-E-MI-33099 |
MNDR | hsa-miR-26a-5p | Primary biliary cirrhosis | MNDR-E-MI-33100 |
MNDR | hsa-miR-26a-5p | Graves disease | MNDR-E-MI-33101 |
MNDR | hsa-miR-26a-5p | Leukemia | MNDR-E-MI-33102 |
MNDR | hsa-miR-26a-5p | Cardiovascular disease | MNDR-E-MI-33103 |
MNDR | hsa-miR-26a-5p | Carotid stenosis | MNDR-E-MI-33104 |
MNDR | hsa-miR-26a-5p | Moyamoya disease | MNDR-E-MI-33105 |
MNDR | hsa-miR-26a-5p | Lung cancer | MNDR-E-MI-33106 |
MNDR | hsa-miR-26a-5p | Down syndrome | MNDR-E-MI-33107 |
MNDR | hsa-miR-26a-5p | Parkinson disease | MNDR-E-MI-33108 |
MNDR | hsa-miR-26a-5p | Niemann-pick disease | MNDR-E-MI-33109 |
MNDR | hsa-miR-26a-5p | Breast cancer | MNDR-E-MI-33110 |
MNDR | hsa-miR-26a-5p | Thyroid cancer | MNDR-E-MI-33111 |
MNDR | hsa-miR-26a-5p | Pituitary neoplasms | MNDR-E-MI-33112 |
MNDR | hsa-miR-26a-5p | Pancreatic cancer | MNDR-E-MI-33113 |
MNDR | hsa-miR-26a-5p | Melanoma | MNDR-E-MI-33114 |
MNDR | hsa-miR-26a-5p | Rectum adenocarcinoma | MNDR-E-MI-33115 |
MNDR | hsa-miR-26a-5p | Epithelial ovarian cancer | MNDR-E-MI-33116 |
MNDR | hsa-miR-26a-5p | Nephroblastoma | MNDR-E-MI-33117 |
MNDR | hsa-miR-26a-5p | Colon cancer | MNDR-E-MI-33118 |
MNDR | hsa-miR-26a-5p | Ischemic attack transient | MNDR-E-MI-33119 |
MNDR | hsa-miR-26a-5p | Colon adenocarcinoma | MNDR-E-MI-33120 |
MNDR | hsa-miR-26a-5p | West nile virus infection | MNDR-E-MI-33121 |
MNDR | hsa-miR-26a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-33122 |
MNDR | hsa-miR-26a-5p | Familial ovarian cancer | MNDR-E-MI-33123 |
MNDR | hsa-miR-26a-5p | Prostate adenocarcinoma | MNDR-E-MI-33124 |
MNDR | hsa-miR-26a-5p | Kidney cancer | MNDR-E-MI-33125 |
MNDR | hsa-miR-26a-5p | Thyroid adenomas | MNDR-E-MI-33126 |
MNDR | hsa-miR-26a-5p | Glomerulonephritis | MNDR-E-MI-33127 |
MNDR | hsa-miR-26a-5p | Carcinoma ductal breast | MNDR-E-MI-33128 |
MNDR | hsa-miR-26a-5p | Glioblastoma | MNDR-E-MI-33129 |
MNDR | hsa-miR-26a-5p | Glioblastoma multiforme somatic | MNDR-E-MI-33130 |
MNDR | hsa-miR-26a-5p | Astrocytoma | MNDR-E-MI-33131 |
MNDR | hsa-miR-26a-5p | Glioma | MNDR-E-MI-33132 |
MNDR | hsa-miR-26a-5p | Chordoma | MNDR-E-MI-33133 |
MNDR | hsa-miR-26a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-33134 |
MNDR | hsa-miR-26a-5p | Osteosarcoma | MNDR-E-MI-33135 |
MNDR | hsa-miR-26a-5p | Inclusion body myositis | MNDR-E-MI-33136 |
MNDR | hsa-miR-26a-5p | Meningioma | MNDR-E-MI-33137 |
MNDR | hsa-miR-26a-5p | Liver cancer | MNDR-E-MI-33138 |
MNDR | hsa-miR-26a-5p | Uterus cancer | MNDR-E-MI-33139 |
MNDR | hsa-miR-26a-5p | Gastric adenocarcinoma | MNDR-E-MI-33140 |
MNDR | hsa-miR-26a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-33141 |
MNDR | hsa-miR-26a-5p | Pituitary adenoma | MNDR-E-MI-33142 |
MNDR | hsa-miR-26a-5p | Lung squamous cell carcinoma | MNDR-E-MI-33143 |
MNDR | hsa-miR-26a-5p | Lung adenocarcinoma | MNDR-E-MI-33144 |
MNDR | hsa-miR-26a-5p | Thyroid carcinoma | MNDR-E-MI-33145 |
MNDR | hsa-miR-26a-5p | Papillary thyroid carcinoma | MNDR-E-MI-33146 |
MNDR | hsa-miR-26a-5p | Bladder urothelial carcinoma | MNDR-E-MI-33147 |
MNDR | hsa-miR-26a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-33148 |
MNDR | hsa-miR-26a-5p | Carcinoma renal cell | MNDR-E-MI-33149 |
MNDR | hsa-miR-26a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-33150 |
MNDR | hsa-miR-26a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-33151 |
MNDR | hsa-miR-26a-5p | Biliary tract cancer | MNDR-E-MI-33152 |
MNDR | hsa-miR-26a-5p | Cholangiocarcinoma | MNDR-E-MI-33153 |
MNDR | hsa-miR-26a-5p | Esophageal cancer | MNDR-E-MI-33154 |
MNDR | hsa-miR-26a-5p | Liver cirrhosis | MNDR-E-MI-33155 |
MNDR | hsa-miR-26a-5p | Lung small cell carcinoma | MNDR-E-MI-33156 |
MNDR | hsa-miR-26a-5p | Encephalopathy bovine spongiform | MNDR-E-MI-33157 |
MNDR | hsa-miR-26a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-33158 |
MNDR | hsa-miR-26a-5p | Myocardial infarction | MNDR-E-MI-33159 |
MNDR | hsa-miR-26a-5p | Heart failure | MNDR-E-MI-33160 |
MNDR | hsa-miR-26a-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-33161 |
MNDR | hsa-miR-26a-5p | Breast invasive carcinoma | MNDR-E-MI-33162 |
MNDR | hsa-miR-26a-5p | Hepatocellular carcinoma | MNDR-E-MI-33163 |
MNDR | hsa-miR-26a-5p | Familiar ovarian carcinoma | MNDR-E-MI-33164 |
MNDR | hsa-miR-26a-5p | B-cell lymphoma | MNDR-E-MI-33165 |
MNDR | hsa-miR-26a-5p | Rheumatoid arthritis | MNDR-E-MI-33166 |
MNDR | hsa-miR-26a-5p | T-cell leukemia | MNDR-E-MI-33167 |
MNDR | hsa-miR-26a-5p | Retinoblastoma | MNDR-E-MI-33168 |
MNDR | hsa-miR-26a-5p | Neuroblastoma | MNDR-E-MI-33169 |
MNDR | hsa-miR-26a-5p | Barrett's adenocarcinoma | MNDR-E-MI-33170 |
MNDR | hsa-miR-26a-5p | Osteoarthritis | MNDR-E-MI-33171 |
MNDR | hsa-miR-26a-5p | Hodgkin lymphoma | MNDR-E-MI-33172 |
MNDR | hsa-miR-26a-5p | Ulcerative colitis | MNDR-E-MI-33173 |
MNDR | hsa-miR-26a-5p | Burkitt lymphoma | MNDR-E-MI-33174 |
MNDR | hsa-miR-26a-5p | Tonsil cancer | MNDR-E-MI-33175 |
MNDR | hsa-miR-26a-5p | Neuromyelitis optica | MNDR-E-MI-33176 |
MNDR | hsa-miR-26a-5p | Skin cutaneous melanoma | MNDR-E-MI-33177 |
MNDR | hsa-miR-26a-5p | Skin melanoma | MNDR-E-MI-33178 |
MNDR | hsa-miR-26a-5p | Acute myelocytic leukemia | MNDR-E-MI-33179 |
MNDR | hsa-miR-26a-5p | Colorectal cancer | MNDR-E-MI-33180 |
MNDR | hsa-miR-26a-5p | Nasopharyngeal carcinoma | MNDR-E-MI-33181 |
MNDR | hsa-miR-26a-5p | Nasopharynx carcinoma | MNDR-E-MI-33182 |
MNDR | hsa-miR-26a-5p | Leukemia lymphoblastic acute | MNDR-E-MI-33183 |
MNDR | hsa-miR-26a-5p | Ovarian epithelial cancer | MNDR-E-MI-33184 |
MNDR | hsa-miR-26a-5p | Diabetic nephropathies | MNDR-E-MI-33185 |
MNDR | hsa-miR-26a-5p | Ependymoma | MNDR-E-MI-33186 |
MNDR | hsa-miR-26a-5p | Cardiac hypertrophy | MNDR-E-MI-33187 |
MNDR | hsa-miR-26a-5p | Hyperalgesia | MNDR-E-MI-33188 |
MNDR | hsa-miR-26a-5p | Nasopharyngeal cancer | MNDR-E-MI-33189 |
MNDR | hsa-miR-26a-5p | Prostatic neoplasms | MNDR-E-MI-33190 |
MNDR | hsa-miR-26a-5p | Sleep deprivation | MNDR-E-MI-33191 |
MNDR | hsa-miR-26a-5p | Epstein-barr virus infections | MNDR-E-MI-33192 |
MNDR | hsa-miR-26a-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-33193 |
MNDR | hsa-miR-26a-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-33194 |
MNDR | hsa-miR-26a-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-33195 |
MNDR | hsa-miR-26a-5p | Chronic pain | MNDR-E-MI-33196 |
MNDR | hsa-miR-26a-5p | Stroke lacunar | MNDR-E-MI-33197 |
MNDR | hsa-miR-26a-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-33198 |
MNDR | hsa-miR-26a-5p | Barrett's carcinogenesis | MNDR-E-MI-33199 |
MNDR | hsa-miR-26a-5p | Breast cancer her3+ negative | MNDR-E-MI-33200 |
MNDR | hsa-miR-26a-5p | Duke C | MNDR-E-MI-33201 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCA1 | Homo sapiens | RR00022107 |
TOP